Raymond James Financial Services Advisors’s Humacyte HUMA Stock Holding History

Raymond James Financial Services Advisors’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$150K	Buy	+27,568	New	+$182K	﹤0.01%	3237

Other funds holding HUMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $23.5B AUM 33.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Raymond James Financial Services Advisors's HUMA Position: Q3 2024 in Review

Raymond James Financial Services Advisors opened a new position in Humacyte (HUMA) in Q3 2024: 27,568 shares worth $150K. The stake represents ﹤0.01% of the portfolio and ranks #3237 among its holdings.

143 funds tracked by Wall St. Rank hold HUMA as of Q3 2024.

Raymond James Financial Services Advisors held 27,568 shares of Humacyte worth $150K as of Q3 2024.
Humacyte was a new Raymond James Financial Services Advisors position in Q3 2024.
Humacyte made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #3237 holding.
143 funds tracked by Wall St. Rank held Humacyte as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.